Keywords

RosiglitazoneMedicineSulfonylureaMetforminType 2 diabetesInternal medicineHazard ratioClinical endpointDiabetes mellitusMyocardial infarctionStroke (engine)InsulinRandomized controlled trialEndocrinologyConfidence interval

Affiliated Institutions

Related Publications

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever , Björn Dahlöf , Neil R Poulter +11 more

The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol loweri...

2003 The Lancet 3773 citations

United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy

Alex Wright , C A Cull , Rury R. Holman +24 more

Because initial insulin therapy induced more hypoglycemic reactions and weight gain without necessarily providing better control, it may be reasonable to start with oral agents ...

1998 Annals of Internal Medicine 388 citations

Publication Info

Year
2009
Type
article
Volume
373
Issue
9681
Pages
2125-2135
Citations
1385
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1385
OpenAlex

Cite This

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. The Lancet , 373 (9681) , 2125-2135. https://doi.org/10.1016/s0140-6736(09)60953-3

Identifiers

DOI
10.1016/s0140-6736(09)60953-3